The regional specificity of these findings aligns with evidence that entorhinal cortex is a site of preclinical neuropathological tau deposition that is elevated for APOE4 carriers [37] and predicts cognitive decline [38], and which undergoes accelerated atrophy in preclinical AD [39]. This evidence concerns the gene MAPT and Alzheimer disease.